Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arterioscler Thromb Vasc Biol ; 36(2): 389-97, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26663396

ABSTRACT

OBJECTIVE: Inflammation in response to oxidized lipoproteins is thought to play a key role in acute coronary syndromes (ACS), but the pattern of immune activation has not been fully characterized. We sought to perform detailed phenotypic and functional analysis of CD8 T lymphocytes from patients presenting with ACS to determine activation patterns and potential immunologic correlates of ACS. APPROACH AND RESULTS: We used polychromatic flow cytometry to analyze the cytokine production profiles of naïve, effector, and memory CD8 T cells in patients with ACS compared with control subjects with stable coronary artery disease. ACS was associated with an altered distribution of circulating CD8(+) T-cell maturation subsets with reduced proportions of naïve cells and expansion of effector memory cells. ACS was also accompanied by impaired interleukin-2 production by phenotypically naïve CD8 T cells. These results were validated in a second replication cohort. Naïve CD8 cells from patients with ACS also had increased expression of programmed cell death-1, which correlated with interleukin-2 hypoproduction. In vitro, stimulation of CD8 T cells with oxidized low-density lipoprotein was sufficient to cause programmed cell death-1 upregulation and diminished interleukin-2 production by naïve CD8 T cells. CONCLUSIONS: In this exploratory analysis, naïve CD8(+) T cells from patients with ACS show phenotypic and functional characteristics of immune exhaustion: impaired interleukin-2 production and programmed cell death-1 upregulation. Exposure to oxidized low-density lipoprotein recapitulates these features in vitro. These data provide evidence that oxidized low-density lipoprotein could play a role in immune exhaustion, and this immunophenotype may be a biomarker for ACS.


Subject(s)
Acute Coronary Syndrome/immunology , CD8-Positive T-Lymphocytes/immunology , Lymphocyte Activation , Acute Coronary Syndrome/blood , Acute Coronary Syndrome/diagnosis , Aged , Biomarkers/blood , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/metabolism , Case-Control Studies , Cells, Cultured , Female , Flow Cytometry , Humans , Immunologic Memory , Immunophenotyping/methods , Interleukin-2/blood , Lipoproteins, LDL/pharmacology , Lymphocyte Activation/drug effects , Male , Middle Aged , Phenotype , Programmed Cell Death 1 Receptor/metabolism
2.
Am J Respir Crit Care Med ; 193(1): 78-85, 2016 Jan 01.
Article in English | MEDLINE | ID: mdl-26372850

ABSTRACT

RATIONALE: Cytomegalovirus (CMV), which is one of the most common infections after lung transplantation, is associated with chronic lung allograft dysfunction and worse post-transplantation survival. Current approaches for at-risk patients include a fixed duration of antiviral prophylaxis despite the associated cost and side effects. OBJECTIVES: We sought to identify a specific immunologic signature that predicted protection from subsequent CMV. METHODS: CMV-seropositive lung transplantation recipients were included in the discovery (n = 43) and validation (n = 28) cohorts. Polyfunctional CMV-specific immunity was assessed by stimulating peripheral blood mononuclear cells with CMV pp65 or IE-1 peptide pools and then by measuring T-cell expression of CD107a, IFN-γ, tumor necrosis factor-α (TNF-α), and IL-2. Recipients were prospectively monitored for subsequent viremia. A Cox proportional hazards regression model that considered cytokine responses individually and in combination was used to create a predictive model for protection from CMV reactivation. This model was then applied to the validation cohort. MEASUREMENTS AND MAIN RESULTS: Using the discovery cohort, we identified a specific combination of polyfunctional T-cell subsets to pp65 that predicted protection from subsequent CMV viremia (concordance index 0.88 [SE, 0.087]). The model included both protective (CD107a(-)/IFN-γ(+)/IL-2(+)/TNF-α(+) CD4(+) T cells, CD107a(-)/IFN-γ(+)/IL-2(+)/TNF-α(+) CD8(+) T cells) and detrimental (CD107a(+)/IFN-γ(+)/IL-2(-)/TNF-α(-) CD8(+) T cells) subsets. The model was robust in the validation cohort (concordance index 0.81 [SE, 0.103]). CONCLUSIONS: We identified and validated a specific T-cell polyfunctional response to CMV antigen stimulation that provides a clinically useful prediction of subsequent cytomegalovirus risk. This novel diagnostic approach could inform the optimal duration of individual prophylaxis.


Subject(s)
Cytomegalovirus Infections/immunology , Lung Transplantation/adverse effects , T-Lymphocytes/immunology , Aged , Cytomegalovirus/immunology , Cytomegalovirus Infections/etiology , Female , Flow Cytometry , Graft Survival/immunology , Humans , Interferon-gamma/immunology , Interleukin-2/immunology , Lysosomal-Associated Membrane Protein 1/immunology , Male , Middle Aged , Proportional Hazards Models , Risk Factors , Tumor Necrosis Factor-alpha/immunology , Viremia/immunology
3.
Ann Surg Oncol ; 20(4): 1128-35, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23456379

ABSTRACT

BACKGROUND: Preprocedure clinical and pathologic factors have failed to consistently differentiate complete response (CR) from progressive disease (PD) in patients after isolated limb infusion (ILI) with melphalan for unresectable in-transit extremity melanoma. METHODS: Multiplex immunobead assay technology (Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel, Millipore Corp., Billerica, MA; and Magpix analytical test instrument, Luminex Corp., Austin, TX) was performed on pre-ILI plasma to determine concentrations of selected cytokines (MIP-1α, IL-1Rα, IP-10, IL-1ß, IL-1α, MCP-1, IL-6, IL-17, EGF, IL-12p40, VEGF, GM-CSF, and MIP-1ß) on a subset of patients (n = 180) who experienced CR (n = 23) or PD (n = 24) after ILI. Plasma from normal donors (n = 12) was also evaluated. RESULTS: Of 180 ILIs performed, 28 % (95 % confidence interval 22-35, n = 50) experienced a CR, 14 % (n = 25) experienced a partial response, 11 % (n = 21) had stable disease, 34 % (n = 61) had PD, and 13 % (n = 23) were not evaluable for response. Tumor characteristics and pharmacokinetics appeared similar between CR (n = 23) and PD (n = 24) patients who underwent cytokine analysis. Although there were no differences in cytokine levels between CR and PD patients, there were differences between the melanoma patients and controls. MIP-1α, IL-1Rα, IL-1ß, IL-1α, IL-17, EGF, IL-12p40, VEGF, GM-CSF, and MIP-1ß were significantly higher in normal controls compared to melanoma patients, while IP-10 was lower (p < 0.001) in controls compared to melanoma patients. CONCLUSIONS: Patients with unresectable in-transit melanoma appear to have markedly decreased levels of immune activating cytokines compared to normal healthy controls. This further supports a potential role for immune-targeted therapies and immune monitoring in patients with regionally advanced melanoma.


Subject(s)
Chemotherapy, Cancer, Regional Perfusion , Cytokines/blood , Extremities , Melanoma/blood , Skin Neoplasms/blood , Adult , Aged , Case-Control Studies , Female , Follow-Up Studies , Humans , Male , Melanoma/drug therapy , Melanoma/mortality , Melphalan/therapeutic use , Middle Aged , Neoplasm Staging , Prognosis , Prospective Studies , Skin Neoplasms/drug therapy , Skin Neoplasms/mortality , Survival Rate
4.
J Clin Pharmacol ; 48(10): 1179-88, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18676693

ABSTRACT

Aplaviroc (GW873140) binds specifically to human cellular CC chemokine receptor 5 (CCR5) and demonstrates potent anti-human immunodeficiency virus activity in vitro in the subnanomolar range. In vitro studies show that aplaviroc selectively inhibits the binding of a particular monoclonal antibody, 45531, to CCR5. Based on this observation, a flow cytometry-based assay was developed to determine percentage CCR5 receptor occupancy (RO). CCR5 receptor occupancy was aplaviroc concentration-dependent and related to anti-human immunodeficiency virus activity in vitro. In the clinical setting, CCR5 receptor occupancy in peripheral blood was >98% in all subjects within 2 to 3 hours of dosing, which is consistent with the peak plasma concentrations of drug. Longitudinal analysis in the drug washout period revealed the time to 50% CCR5 receptor occupancy averaged >100 hours, in both human immunodeficiency virus-positive and human immunodeficiency virus-negative subjects, substantially longer than the plasma pharmacokinetic half-life of 3 hours. The duration of CCR5 receptor occupancy appeared to be dose-dependent and associated with antiviral activity as measured by plasma human immunodeficiency virus RNA nadir following 10 days of multiple dose administration. These data demonstrate that the analysis of CCR5 receptor occupancy, in addition to conventional plasma-based pharmacokinetic measures, provides an informative tool to assist in evaluating the pharmacodynamic and antiviral effects of cellular CC chemokine receptor antagonists.


Subject(s)
Benzoates/pharmacology , HIV Fusion Inhibitors/pharmacology , HIV Infections/drug therapy , Piperazines/pharmacology , Receptors, CCR5/drug effects , Spiro Compounds/pharmacology , Adult , Antibodies, Monoclonal/metabolism , Benzoates/administration & dosage , Benzoates/pharmacokinetics , Diketopiperazines , Dose-Response Relationship, Drug , Double-Blind Method , Female , Flow Cytometry , HIV Fusion Inhibitors/administration & dosage , HIV Fusion Inhibitors/pharmacokinetics , Half-Life , Humans , Male , Middle Aged , Piperazines/administration & dosage , Piperazines/pharmacokinetics , Protein Binding/drug effects , RNA, Viral/blood , RNA, Viral/drug effects , Receptors, CCR5/metabolism , Spiro Compounds/administration & dosage , Spiro Compounds/pharmacokinetics , Time Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...